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incidence and epidemiology
The European incidence of malignant melanoma varies from 3 to
5/100 000/year in Mediterranean countries to 12–25 (and rising)
in Nordic countries. Increased ultraviolet (UV) light exposure of
a genetically predisposed population seems to be, at least in part,
responsible for an ongoing increase in incidence with signs of sta-
bilisation of mortality over recent decades, except in elderly males
[1]. There is a disparity in the mortality-to-incidence ratios
between Western and Eastern European countries [2], implying a
need to improve prevention, especially in Eastern Europe.
UV irradiation was identiﬁed as a major carcinogen involved
in melanoma genesis. Prevention of UV exposure, including the
regular use of sunscreen, has been shown to diminish the
incidence of primary cutaneous melanomas in an Australian
population [3].
diagnosis
Suspicious lesions are characterised by Asymmetry, Border
irregularities, Colour heterogeneity, Dynamics, (dynamics or evo-
lution in colours, elevation or size) (‘ABCD rule’) [4]. Today,
many primary melanomas have a diameter of <5 mm [5].
The ugly duckling ‘concept’ [6] helps to identify melanomas,
because naevi in the same individual tend to resemble one
another and melanomas often do not ﬁt the individual’s naevus
pattern.
Dermoscopy by an experienced physician enhances the diag-
nostic accuracy [II, B] [7]. An automated video-dermoscopy
system can provide improved diagnostic accuracy for patients
with multiple atypical naevi in the follow-up.
Diagnosis should be based on a full-thickness excisional biopsy
with a minimal side margin. Processing by an experienced path-
ology institute is mandatory.
The histology report should follow the American Joint
Committee on Cancer (AJCC) classiﬁcation [8], and include: in-
formation on the maximum thickness in millimetres (Breslow),
information on mitotic rate in case of a tumour thickness below
1 mm, presence of ulceration, presence and extent of regression
and clearance of the surgical margins [II, A]. In addition, infor-
mation on anatomical site (including extra-cutaneous sites, such
as mucosa, conjunctiva) and degree of sun damage is necessary.
It should also include the melanoma type (superﬁcial spreading
melanoma, lentigo maligna melanoma, acral lentiginous melan-
oma, nodular melanoma and others). In rare situations, melano-
mas may derive from dermal melanocytes (melanoma arising
from giant congenital naevus, malignant blue naevus) [9].
Superﬁcial spreading and nodular melanomas present a higher
frequency of BRAF and NRAS mutations than other melanoma
types [10]. Acral lentiginous melanoma and mucosal melanomas
of the genital region have a certain probability to present c-Kit
mutations [11].
Mutation testing for treatable mutations is mandatory in
patients with advanced disease (unresectable stage III or stage IV,
and highly recommended in high-risk resected disease stage IIc,
stage IIIb–IIIc) [V, A]. If the tumour is BRAF-wild type, testing
for NRAS mutations c-kit mutation should be considered [V, A].
Mutational testing of primary tumours without metastases
is not recommended. Mutation analysis must be carried out in
accredited (certiﬁed) institutes that have careful quality controls.
staging and risk assessment
Physical examination with special attention to other suspicious
pigmented lesions, tumour satellites, in-transit metastases, re-
gional lymph node (LN) and systemic metastases is mandatory.
In low-risk melanomas (pT1a) no other investigations are neces-
sary. In higher tumour stages (pT1b–pT3a), imaging (ultrasound
for locoregional LNmetastasis) and, in pT stages >pT3a, computed
tomography (CT) or positron emission tomography (PET) scans
are recommended before surgical treatment and sentinel node
biopsy [III, C].
The reﬁned version of the AJCC staging and classiﬁcation
system, which includes sentinel node staging, is the only inter-
nationally accepted classiﬁcation system [8, 12] (Table 1).
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treatment of localised disease
Wide excision of primary tumours with safety margins of 0.5 cm
for in situ melanomas, 1 cm for tumours with a thickness of up
to 2 mm, and 2 cm for thicker tumours, is recommended [13]
[II, B]. Modiﬁcations, with reduced safety margins, are acceptable
for preservation of function in acral and facial melanomas and
should be carried out with micrographic surgery.
Elective lymphadenectomy or irradiation to the regional LNs
should not be carried out routinely [II, B].
Sentinel LN biopsy in melanoma with a tumour thickness of
>1 mm and >0.75 mm and additional risk factors such as ulcer-
ation or mitotic rate (pT1b) are recommended for precise
staging [II, B] [14]. A complete lymphadenectomy of regional
LNs must be discussed with the patient, if the sentinel node was
found positive for metastases [III, C]. However, this procedure
offers just a relapse-free survival (RFS) beneﬁt without proven
effect on overall survival (OS) [15]. Sentinel LN biopsy should
be carried out only in experienced centres.
Many well-designed clinical trials have investigated the
impact of adjuvant therapy in patients with high-risk primary
melanoma (stage IIB/C) or completely resected LN metastases
(stage III) [6]. A number of prospective randomised trials have
investigated adjuvant treatment with low, intermediate and high
doses of interferon-α (IFN-α) [16, 17].
A meta-analysis of 14 randomised, controlled trials, investigat-
ing adjuvant IFN therapy involving 8122 patients, showed statis-
tically signiﬁcant absolute improvement in both disease-free
survival [hazard ratio (HR) 0.82] and OS (HR 0.89), with no clear
indication to recommend a certain dose or treatment duration
[18]. Since pegylated IFN-α (PegIFN-α) is suitable for long-term
therapy, the European Organisation for Research and Treatment
of Cancer (EORTC) has initiated a large prospective randomised
trial to investigate the protective effect of PegIFN-α-2b in the ad-
juvant setting [19]. A total of 1256 patients with resected stage III
melanoma were randomised to receive observation or PegIFN-α
therapy [19]. Randomisation was stratiﬁed for microscopic (N1)
versus macroscopic (N2) nodal involvement, number of positive
nodes, ulceration and tumour thickness. The IFN group received
an induction-IFN-weekly dose of 6 μg/kg for the ﬁrst 8 weeks,
and the dose was then reduced to 3 μg/kg per week for 5 years
[19]. At 3.8 years of median follow-up, RFS was signiﬁcantly
improved by 18% in the PegIFN-α-2b arm, compared with obser-
vation; the 4-year RFS rate was 45.6% versus 38.9%. OS was un-
changed in the two groups. In stage III–N1a (micrometastases
Table 1. AJCC staging system of melanoma
T classification Thickness (mm) Ulceration status/mitosis
T1 ≤1.0 a: without ulceration and mitosis <1/mm²
b: with ulceration or mitoses ≥1/mm²
T2 1.01–2.0 a: without ulceration
b: with ulceration
T3 2.01–4.0 a: without ulceration
b: with ulceration
T4 >4.0 a: without ulceration
b: with ulceration
N classification No. of metastatic nodes Nodal metastatic mass
N0 0 N/A
N1 1 node a: micrometastasisa
b: macrometastasisb
N2 2–3 nodes a: micrometastasisa
b: macrometastasisb
c: in transit metastases/satellites ‘without’metastatic
nodes
N3 4 or more metastatic nodes, or matted nodes, or in
transit metastases/satellites ‘with’metastatic nodes
M classification Site Serum LDH
M0 No distant metastasis N/A
M1a Distant skin, subcutaneous, or nodal metastases Normal
M1b Lung metastases Normal
M1c All other visceral metastases
Any distant metastasis
Normal
Elevated
Reprinted with permission. © 2009 American Society of Clinical Oncology. All rights reserved.
aMicrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if carried out).
bMacrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross
extracapsular extension.
AJCC, American Joint Committee on Cancer; N/A, not applicable; LDH, lactate dehydrogenase.
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detected in the sentinel node), both RFS and distant metastases-
free survival (DMFS) were prolonged in the PegIFNα-2b arm,
whereas in stage III-N1b (macroscopic metastases), there was
no beneﬁt [19]. An update of this trial, with median follow-up of
7.6 years, has shown that IFN therapy had a signiﬁcant impact on
RFS, DMFS and OS (HR 0.59 = 0.006) in a sub-population of
patients with micrometastases and primary ulcerated melanomas
[20]. Therefore, while awaiting the results of prospective rando-
mised trials, in this patient population, PegIFN-α can be recom-
mended if the individual patient tolerates it well [II, B]. Adjuvant
treatment in patients with resected macroscopic node involve-
ment is preferentially applied in the context of randomised clinic-
al trials in specialised centres. However, high-dose IFN-α-2b is
an approved indication for this therapeutic situation. A meta-
analysis on adjuvant therapy of melanoma with IFNs, however,
did not demonstrate an improved efﬁcacy of high-dose IFN com-
pared with low- or intermediate-dose IFNs [18].
Long-term therapy with ipilimumab, an antibody blocking
CTLA4 and thus activating T lymphocytes to mount an immune
response against tumour cells, has improved RFS (HR 0.75;
median RFS 26.1 versus 17.1 months, with 3-year RFS rates of
46.5% versus 34.8%, P = 0.0013) in the adjuvant setting also for
N1b and higher stages. However, the treatment with a dose of 10
mg/kg every 3 weeks for 4 doses, then every 3 months for up to 3
years, was associated with a number of severe and long-lasting
adverse reactions including colitis and endocrinopathies.
Therefore, additional trials are mandatory and the respective
patient population should be referred to centres offering trial
participation [21].
Adjuvant chemotherapy, mistletoe extracts, viscum album and
hormone therapies are not beneﬁcial at all [22]. Adjuvant therapy
with other cytokines including interleukin-2, tumour vaccination,
immunochemotherapy and BRAF inhibitors is experimental and
not to be used outside controlled clinical trials. The application of
BRAF inhibitors is associated with cutaneous neoplasms such as
keratoacanthomas, squamous cell carcinomas and melanomas
[23–25], which precludes use outside carefully monitored clinical
trials. Radiotherapy for local tumour control should be consid-
ered in: cases of inadequate resection margins of lentigo maligna
melanoma [26], in R1 resections of melanoma metastases (when
surgery is not adequate), or after resection of bulky disease
[III, B]. A prospective randomised trial has demonstrated that
postoperative irradiation after LN dissection reduces the risk for
relapse in the irradiation ﬁeld by ∼50%, but has no impact on
RFS and OS [27]. Treatment decisions should be made in an
interdisciplinary team.
treatment of locoregional disease
In the case of isolated locoregional LN metastases, surgical
removal, including the surrounding LN region is indicated [III,
C]; removal of the tumour-bearing LN alone is insufﬁcient. In
high-risk situations such as multiple bulky LN metastases, post-
operative radiotherapy can improve local tumour control, but
has no impact on RFS and OS [27, 28].
However, before undertaking additional aggressive local surgi-
cal treatments, a detailed staging investigation, that includes
high-resolution imaging techniques, such as PET, CT or magnetic
resonance imaging is necessary to exclude distant metastases
[4] [III, B]. In unresectable in-transit cases, other locoregional
approaches, such as electrochemotherapy [29] or intralesional
therapy with replicating herpes virus [Talimogene laherparepvec
(T-Vec)] [30], preferentially in the context of a clinical trial,
should be considered.
Surgical removal or stereotactic irradiation therapy might be
curative in a few patients and is recommended in the case of a
single metastasis in parenchymal organs, including the central
nervous system.
Non-resectable in-transit metastases or inoperable primary
tumours of the limbs, without additional metastases, may be
treated with isolated limb perfusion using melphalan and/or
tumour necrosis factor-α [III, C]. Such treatment requires major
surgery and should be restricted to centres of excellence. Radiation
therapy, electrochemotherapy [29] or intralesional therapy, with
replicating T-Vec [30], may also be used [V, D], [27, 28].
treatment of systemic metastatic disease
(stage IV)
New therapeutic strategies, such as immunotherapy, that utilise
antibodies that bind to checkpoint inhibitors of T-cell activation,
have demonstrated impressive efﬁcacy. CTLA-4 blocking agents
like ipilimumab, the anti PD-1 antibodies, such as nivolumab
and pembrolizumab, as well as selective BRAF inhibitors, such as
vemurafenib, encorafenib and dabrafenib (used alone and/or in
combination with MEK inhibitors like binimetinib, cobimetinib
and trametinib [31, 32]), have demonstrated impressive anti-
tumour activity [33–39]. Therefore, immunotherapy and kinase
inhibitors are the backbone of systemic therapy. Chemotherapy is
considered a second-line or bridging treatment option.
Tumour tissues, preferentially of metastatic lesions, should be
screened for mutations of BRAF V600. If that is negative,
further molecular testing can be carried out for NRAS, c-Kit
(mucosal and acrolentigenous primaries) GNA11 or GNAQ
(uveal primary); this helps to direct patients to the appropriate
targeted treatment or clinical trial. There are early signals from a
phase II clinical trial that patients with metastatic melanomas,
carrying NRAS mutation, may beneﬁt from MEK kinase-inhibi-
tor therapy [40]. The additional analysis for PDL-1 expression
helps to enrich the population of patients who beneﬁt from
anti-PD1 therapy, but is not powerful enough to exclude
patients from anti-PD1 treatment [39, 41].
The recommendations for ﬁrst-line treatment of metastatic
disease are under debate. Reasonable approaches include anti-
PD1 therapies and, for BRAF-mutated melanomas, combinations
of BRAF inhibitors with MEK inhibitors. BRAFi/MEKi inhibitor
combos offer high response rates (70%) and rapid response in-
duction associated with symptom control, with a progression-free
survival (PFS) of ∼12 months. Anti-PD1 therapy, and to a lesser
extent ipilimumab, offer lower response rates in the range, but
many responses are durable [42].
In patients with BRAF-wild-type (wt) disease, ipilimumab
has been the standard treatment based on a survival beneﬁt with
a ∼10% higher survival rate at 1, 2 and 3 years [36]. Based on
very recent randomised trial results, comparing anti-PD1 antibody
therapies to ipilimumab, anti-PD1 antibody therapy is the pre-
ferred ﬁrst-line treatment of patients with BRAF-wt disease [42].
These therapies also demonstrate efﬁcacy for patients with other
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BRAF mutations [37]. Anti-PD1 therapies are also recommended
as a second-line treatment, after ipilimumab failure [43, 44].
The anti-PD1 antibody nivolumab was compared with the
reference chemotherapy dacarbazine in a double-blind rando-
mised clinical trial with BRAF-wt patients. This trial showed a
1-year survival rate of 72.9% in the nivolumab group, compared
with 42.1% in the dacarbazine group (HR for death, 0.42;
P < 0.001) [39]. Nivolumab and pembrolizumab present an ex-
cellent safety proﬁle, resulting in a favourable risk/beneﬁt ratio.
The most frequent adverse events included fatigue, pruritus and
nausea. Both molecules have been compared with standard che-
motherapies in a second-line setting after ipilimumab therapy.
They demonstrated favourable efﬁcacy, with prolonged PFS and
better response rates, than the chemotherapy option [43–45].
Pembrolizumab (at a dose of 10 mg/kg of body weight) every
2 or 3 weeks was compared with ipilimumab in a randomised
clinical trial. The 6-month PFS rates were ∼47% for pembrolizu-
mab, independent from the dose, and 26.5% for ipilimumab
(HR for disease progression, 0.58; P < 0.001 for both pembroli-
zumab regimens versus ipilimumab). Estimated 12-month
survival rates were ∼70% for pembrolizumab, versus 58%. The
response rate was ∼33% for pembrolizumab, compared with
11.9% for ipilimumab [42].
In a double-blinded prospective randomised trial, nivolumab
was compared with ipilimumab and the ipilimumab/nivolumab
combination. The anti-PD1 antibody alone or in combination
demonstrated improved PFS (ipilimumab: 2.9, nivolumab: 6.9,
combination: 11.5 months) and response rates.
PDL-1 expression was a relevant marker in this context, because
there was no difference in PFS between anti-PD1 antibody therapy
versus a ipilimumab/nivolumab combination, in the PDL-1 posi-
tive population. The study was not powered to distinguish between
the efﬁcacy of nivolumab and the ipilimumab/nivolumab combo.
The ﬁnal clinical implications of this study, including the question
about the superiority of combined anti-PD1/CTLA-4 therapy
versus sequential anti-PD1/CTLA-4 therapy, remain open until
the survival data are mature [41].
If the patient suffers from symptomatic, bulky metastases from
a BRAF-V600-mutated melanoma, a combination of BRAFi and
MEKi is a valid treatment option in ﬁrst and second lines. It has a
high chance for rapid response and offers improvements in
quality of life [37–39, 41]. There are no mature data to guide deci-
sion making regarding the sequencing of checkpoint inhibitors
and kinase-inhibitor combinations, in patients with BRAF-
mutant metastatic melanoma. Emerging data suggest that BRAF
inhibition is effective following immunotherapy, and checkpoint
inhibitors are still effective in patients who have progressed on
kinase-inhibitor therapy. Kinase inhibitors [46] and ipilimumab
and/or anti-PD1 antibody therapy [47] can be safely used even in
patients with symptomatic brain metastases, in fact it has shown
signiﬁcant efﬁcacy in this area [48]. Stereotactic irradiation of pro-
gressive brain metastases is reasonable if systemic therapy can
achieve partial disease control.
In the context of new developments and medical progress, there
are continuously new experimental treatment options for patients
with advanced metastatic melanoma, including combined therap-
ies with anti-CTLA4 and anti-PD1 antibodies, with intralesional
therapies and small molecules. Therefore, patients should
preferentially be referred to centres of excellence that provide a
comprehensive clinical trial programme.
If clinical trials or new compounds are not available, cytotoxic
drugs such as dacarbazine (DTIC), temozolomide, taxanes,
fotemustine, platin derivatives or others, cytokines (IFNs, inter-
leukin-2) or combinations may be applied. DTIC is still consid-
ered a reference drug in this situation. In aggressive metastatic
disease, multi-agent polychemotherapy, containing paclitaxel
and carboplatin or cisplatin, vindesine, and DTIC may provide
mostly short-lived partial responses and/or disease stabilisations
in a meaningful number of patients. Despite a better initial
control rate, no survival beneﬁt has been shown with polyche-
motherapy compared with monochemotherapy.
Surgery of visceral metastases may be appropriate for selected
cases with good performance status and isolated tumour manifes-
tations. In principal, the goal is R0 resection in these patients.
Palliative radiotherapy should be considered, especially for
symptomatic brain or localised and painful bone metastases.
Stereotactic irradiation is preferred to whole brain irradiation in
case of brain metastases [28].
In general, stage IV melanoma patients need to be treated and
discussed in an interdisciplinary tumour board, within centres
that have broad experience in this disease (Table 2).
personalised medicine
Biomarkers such as mutations (NRAS, c-Kit, BRAF) are already
indispensable today for proper management of advanced mel-
anoma. Additional mutations and the overall mutation rate
might provide additional molecular predictive markers in the
near future. Based on the recent data of anti-PD1 efﬁcacy in
PDL-1-positive advanced melanoma [41], this parameter, which
is determined by immunohistochemistry and reﬂects the pres-
ence of T cells in the tumour microenvironment, might soon be
relevant. We assume that treatment algorithms for advanced
melanoma may evolve in a paradigm for precision medicine in
the context of targeted and immunotherapy [42].
patient information and follow-up
Melanoma patients should be advised to avoid sunburn,
extended unprotected solar or artiﬁcial UV exposure, and to
have lifelong, regular self-examinations of the skin and periph-
eral LNs. Patients must be aware that family members have an
increased melanoma risk [III, B]. There is no recommendation
for genetic testing.
During melanoma follow-up, patients are clinically moni-
tored in order to detect a relapse and to recognise additional
skin tumours, especially secondary melanomas, as early as pos-
sible [4] [III, B]. However, it remains to be determined whether
this strategy leads to improved survival rates, especially in this
new era of systemic therapies for stage IV disease. Eight percent
of all melanoma patients develop a secondary melanoma within
2 years of the initial diagnosis [49]. Melanoma patients also
have an increased risk for other skin tumours. In patients with
lentigo maligna melanomas, 35% of patients develop another
cutaneous malignancy within 5 years [26].
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There is currently no consensus on the frequency of follow-up
examinations and the use of imaging techniques. Recommendations
vary from follow-up visits every 3 months, during the ﬁrst 3 years
and every 6–12 months thereafter, to no organised follow-up at all.
We encourage consultation of the respective national guidelines.
Intervals between controls may be tailored according to the indivi-
dual’s risk and the personal needs of the patient [50].
Since patients with a thin primary melanoma have only a small
risk of relapse, routine imaging techniques are deﬁnitively not
recommended for this patient population. In high-risk patients,
(e.g. those with thick primary tumours, or following treatment of
metastases) ultrasound of LNs, CT or whole-body PET/PET–CT
scans may lead to an earlier diagnosis of regional or systemic
relapses [51]. The impact of radiological exams upon survival has
not been demonstrated so far [52]. However, targeted therapy and
immunotherapy demonstrate favourable effects in patients with
low tumour burden, who can be identiﬁed by high-resolution
imaging during follow-up. Rising serum S-100 has a higher speciﬁ-
city for disease progression than lactate dehydrogenase, and is
therefore the most accurate blood test in the follow-up of melan-
oma patients [53], if any blood test is recommended at all [IV, D].
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical prac-
tice guidelines development. The relevant literature has been
selected by the expert authors. A summary of recommendations
is shown in Table 3. Levels of evidence and grades of recommen-
dation have been applied using the system shown in Table 4.
Statements without grading were considered justiﬁed standard
clinical practice by the experts and the ESMO faculty. This manu-
script has been subjected to an anonymous peer review process.
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Table 2. Treatment modalities for melanoma metastases
Number and localisation of the metastases Treatment modalities
1st choice
2nd choice
3rd choice
Grade of recommendation
In-transit metastases (few) (pTXN2cM0) Surgical removal C
Radiotherapy C
In-transit metastases (multiple, >5) (pTXN2cM0) Perfusion of the extremitya D
Radiotherapy D
T-Vec (Talimogene laherparepvec) D
Electrochemotherapy D
Systemic therapya D
Locoregional LNs (pTxN1a, 2a) Discuss Regional lymph node dissection and trial
participation
B
Additional Interferon alpha treatmenta B
Locoregional LNs (pTxN2b, 2c, 3) Radical lymphadenectomy,
in case of incomplete resection:
irradiation,
C
Consider trial participation C
Solitary central nervous system metastases (pTxNxM3) Neurosurgical removal D
Stereotactic irradiationa
(according to localisation this could also be the 1st choice)
or other local treatment approaches
D
Consider clinical trial participation
Solitary lung/liver/kidney and other metastases (pTxNxM1) Surgical removal D
Consider clinical trial participation
Systemic therapya D
Multiple metastases (pTxNxM1a–1c) Consider clinical trial participation
Systemic therapya B
Painful bone metastases (pTxNxM1a–1c) Consider clinical trial participation
Radiotherapy C
Bone-modifying agents
aThese therapies should be preferentially carried out at specialised centres.
LNs, lymph nodes.
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Table 4. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of
good methodological quality (low potential for bias) or meta-
analyses of well-conducted randomised trials without
heterogeneity
II Small randomised trials or large randomised trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs,… ), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
aBy permission of the Infectious Diseases Society of America [54].
Table 3. Summary of recommendations
Diagnosis
• Diagnosis should be based on a full-thickness excisional biopsy with a
small side margin [II, A].
• The histology report should include at least: information on the type
of melanoma, actinic damage, maximum vertical thickness in
millimetres, information on mitotic rate in case of pT1, presence of
ulceration, presence and extent of regression and clearance of the
surgical margins [II, A].
• Physical examination with special attention to other suspicious
pigmented lesions, tumour satellites, in-transit metastases, regional LN
and distant metastases is mandatory. In low-risk melanomas (pT1a), no
other investigations are necessary. In higher tumour stages, imaging is
recommended in order to allow proper staging [III, C].
Treatment of localised disease
• Wide excision of primary tumours with safety margins of
0.5 cm for in situmelanomas, of 1 cm for tumours with a tumour
thickness up to 2 mm and 2 cm for thicker tumours is recommended
[II, B].
• Sentinel LN biopsy in melanoma with a tumour thickness of >1 mm
and/or ulceration is recommended for precise staging [II, B]. It should be
discussed in patients with a pT1b with a tumour thickness >0.75 mm.
• Patients with resected stage III melanomas should be evaluated for
adjuvant interferon therapy [II, B]. Subgroup analyses suggest patients
with microscopic regional nodal involvement and/or ulcerated
primaries are most likely to benefit from adjuvant IFN. In stage IIIB
and higher, participation in clinical trials should be encouraged.
• Surgical removal or stereotactic irradiation of locoregional recurrence
or single distant metastasis should be considered in fit patients, as a
therapeutic option, offering potential for long-term disease control
[III, C].
Treatment of systemic metastatic disease (stage IV)
• Patients with metastatic melanoma should have metastasis
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